SCHEMBL119144

SCHEMBL119144

COC(=O)c1ccc(S(=O)(=O)NCc2ccccc2)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.61
ALDH1A1 P00352 4/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C19 P33261 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
POLB P06746 1/20 0.54
LMNA P02545 3/20 0.52
PKM P14618 1/20 0.51
MAPT P10636 4/20 0.49
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
TP53 P04637 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108588 0.86 POLB (0.55) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL119541 0.85 SMN1; SMN2 (0.54) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL119909 0.81 LMNA (0.77) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL119461 0.79 POLB (0.72) ALDH1A1CYP1A2CYP2C19SMN1; SMN2POLB
SCHEMBL29123938 0.78 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2POLBPKMMAPT
SCHEMBL13186462 0.76 MAPT (0.65) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL3850206 0.76 POLB (0.72) ALDH1A1CYP1A2SMN1; SMN2POLBLMNA
SCHEMBL975460 0.76 CA9 (0.73) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL16715360 0.75 ALDH1A1 (0.74) FABP4ALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL3720799 0.75 VCAM1 (0.60) ALDH1A1CYP1A2CYP2C19SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 FABP4 918/4885ALDH1A1 1996/4885CYP1A2 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.